SCHEMBL3559668

SCHEMBL3559668

COc1cnc(-c2cncnc2)c2[nH]cc(C(=O)C(=O)O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.43
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2B6 P20813 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNH2 Q12809 1/20 0.38
ERN1 O75460 2/20 0.36
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
SYK P43405 1/20 0.33
JAK3 P52333 5/20 0.32
JAK2 O60674 4/20 0.32
ECE1 P42892 1/20 0.32
CTSA P10619 1/20 0.32
AAK1 Q2M2I8 2/20 0.32
NEK1 Q96PY6 1/20 0.32
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12215482 0.91 CYP2C9 (0.41) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL1472911 0.81 CYP2C9 (0.46) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL12238398 0.80 CYP2C9 (0.47) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL1472698 0.80 CYP2C9 (0.61) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL10326256 0.80 CYP2C9 (0.47) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL1763206 0.80 CYP2C9 (0.74) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL1550197 0.79 CYP2C9 (0.47) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
Water SCHEMBL1733706 0.79 CYP2C9 (0.60) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL2628952 0.79 CYP2C9 (0.47) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6
SCHEMBL29616351 0.79 CYP2C9 (0.47) CYP2C9CYP3A4CYP1A2CYP2C8CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS CYP2C9 3136/4885CYP3A4 1204/4885CYP1A2 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.